SPKM 001
Alternative Names: SPK-001; SPKM-001Latest Information Update: 02 May 2024
At a glance
- Originator Institut Pasteur
- Developer SpikImm
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 07 Dec 2022 SpikImm completes a phase I trial in COVID-2019 infections (In volunteers) (SC)
- 01 Dec 2022 Phase-I clinical trials in COVID-2019 infections (In volunteers) (SC), prior to December 2022
- 13 Apr 2022 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by SpikImm